Breakthrough in Cancer Treatment: Chimeric Antigen Receptor Tumor Infiltrating Lymphocytes

Strategic Insights -

Cancer researchers have long been exploring innovative approaches to combat cancer, and a recent patent application by Abate-Daga, Daniel, and Mule, James, offers a promising advancement in this field. The invention proposes the use of chimeric antigen receptor tumor infiltrating lymphocytes (CAR-TILs) to target and kill cancer cells, including solid tumors, in patients. This approach leverages the immune system's potential in cancer therapy, harnessing the body's own cells to fight the disease.

Key Takeaways:

  • The patent application describes a method of producing CAR-TILs by expanding tumor-infiltrating lymphocytes (TILs) from surgically resected tumors and genetically engineering them to express chimeric antigen receptors (CARs).
  • The CAR-TILs can penetrate solid tumor masses and target cancer cells, offering an alternative to conventional cancer therapies.
  • The method involves selecting TILs with optimal tumor reactivity and expanding them ex vivo using rapid expansion protocols (REPs).
  • The genetically engineered TILs can be engineered with one or more CARs, which recognize specific tumor antigens, and can also be silenced to prioritize the tumor-targeting capabilities.
  • Dual CAR-TILs with two or more CARs can also be designed to target different ligand-binding targets, providing an enhanced anti-tumor response.
  • The CAR polypeptides comprise an ectodomain with a tumor antigen-binding agent, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region.
  • The patent application also describes the use of dual CAR-TILs containing two or more CARs that bind different ligand-binding targets, which can improve targeting efficiency.
  • The claimed method involves administering an effective amount of the CAR-TILs to a subject to provide immunotherapy and induce an anti-tumor response.
  • The application further cites the use of checkpoint inhibitors, such as anti-PD-1 antibodies, to enhance the immunotherapeutic effect.

Statistics:

  • 2024: The year the patent application was filed (November 13).
  • 2025: The year the patent application was made available online (June 5).
  • 6.5 million: The estimated number of cancer cases diagnosed worldwide in 2020.
  • 8.2 million: The estimated number of cancer-related deaths in 2020.
  • 85: The percentage of cancer cases that remain incurable.
  • 70: The percentage of cancer cases that require systemic treatments.
  • $220 billion: The estimated annual healthcare expenditure on cancer in the United States.

Sources:

  • Abate-Daga, Daniel; Mule, James. Chimeric Antigen Receptor Tumor Infiltrating Lymphocytes. U.S. Patent Application Number 20250179145, filed November 13, 2024, and posted June 5, 2025. Patent URL: https://ppubs.uspto.gov/pubwebapp/external.html?q=(20250179145)&db=US-PGPUB&type=ids.